Facebook
  • Home page
  • About Us
  • Our Products
  • Careers
  • NewsRoom
  • Privacy Policy
  • Integrated Management System
  • Communication with Costumers
  • العربية
  • Home page
  • About Us
  • Our Products
  • Careers
  • NewsRoom
  • Privacy Policy
  • Integrated Management System
  • Communication with Costumers
  • العربية
Facebook
Home by Therapeutic Group Genitounrinary drugs

UROMAX

Uromax
UROMAX-SYRUP
  • Uromax
  • UROMAX-SYRUP

Product Information

Composition:

Uromax 5: Each film coated tablet contains 5 mg solifenacin succinate, corresponding to 3.8 mg solifenacin.

Uromax 10: Each film coated tablet contains 10 mg solifenacin succinate, corresponding to 7.5 mg solifenacin.

Each 1 ml oral suspension contains: solifenacin succinate, equivalent to 0.75 mg solifenacin.

Therapeutic indications:

Symptomatic treatment of urge incontinence and / or increased urinary frequency and urgency as may occur in patients with overactive bladder syndrome.

Dosage:

Adults, including the elderly:

The recommended dose is 5 mg solifenacin succinate once daily. If needed, the dose may be increased to 10 mg solifenacin succinate once daily.

Paediatric population (age 2 to 18 years):
The recommended dose of solifenacin oral suspension is determined based on patient weight. Treatment should be initiated at the recommended starting dose. Thereafter, the dose may be increased to the lowest effective dose.
The maximum dose should not be exceeded. During long-term therapy, patients should be periodically evaluated for treatment continuation and for potential dose adjustment, at least annually or more frequently if indicated.
The doses according to the patient›s body weight are found

 

                         Weight range (kg)                                Starting dose (ml)                             Maximum dose (ml)

                             4                                                           2                                                          9 – 15

                            5                                                            3                                                        > 15 to 30

                           6                                                             3                                                        > 30 to 45

                           8                                                             4                                                        > 45 to 60

                          10                                                            5                                                        > 60

Patients with renal impairment:

No dose adjustment is necessary for patients with mild to moderate renal impairment (creatinine clearance > 30 ml / min).

Patients with severe renal impairment (creatinine clearance ≤ 30 ml / min) should be treated with caution and receive no more than 5 mg once daily.

Patients with hepatic impairment:

No dose adjustment is necessary for patients with mild hepatic impairment. Patients with moderate hepatic impairment (Child-Pugh score of 7 to 9) should be treated with caution and receive no more than 5 mg once daily.

Potent inhibitors of cytochrome P450 3A4:

The maximum dose of solifenacin succinate should be limited to 5 mg when treated simultaneously with ketoconazole or therapeutic doses of other potent CYP3A4-inhibitors e.g. ritonavir, nelfinavir, itraconazole

Method of administration:

Uromax should be taken orally and should be swallowed whole with liquids. It can be taken with or without food.

Presentation:

Uromax 5: A pack of 30 F.C.T.

Uromax 10: A pack of 30 F.C.T.

Glass Bottle contains 100 ml oral suspension.

Categories: Genitounrinary drugs, Suspended syrup, Tablets
Share:
OTOCALM

Otocalm
Zetrizin plus
ZETRIZIN PLUS

Related products

Quick View View products

CALCICOMB

Artral Plus
Quick View Read more

ِARTRAL PLUS

ZINC ALFARES
Quick View Read more

ZINC ALFARES

Levozetrin
Quick View Read more

LEVOZETRIN

Phone number

+963 11 584 2222

address

At-Tall District Syria, Sednayah Road، Mneen, Syria

e-mail

info@alfarespharma.com

logo

Contact Us

  • 33070, Damascus, Syria
  • +963 11 584 2224
  • +963 11 584 2225
  • info@alfarespharma.com
  • Saturday-Thursday 7:30 am - 3:30 pm

visit us

All Right Reseved . Alfares Pharmaceuticals 2021